Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Glioblastoma 47Brain Neoplasms 24Central Nervous System Neoplasms 22Astrocytoma 16Glioma 15Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Lymphoma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, AIDS-Related 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Ependymoma 2Burkitt Lymphoma 2Uveal Melanoma 1Solid Tumor 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × Lomustine × Clear all
NCT00527657 2018-11-14

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

M.D. Anderson Cancer Center

Phase 1 Completed
17 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡